Disha Malani

University of Helsinki — Finland

Medicine · Health Sciences

14h-index1.5kcitations112works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Drug Transport and Resistance Mechanisms(39), Acute Myeloid Leukemia Research(35), RNA Interference and Gene Delivery(26), Cancer therapeutics and mechanisms(26), Cancer Genomics and Diagnostics(21)

Publications112 total

Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism
Cell Death and Disease·2025· 3 citedOpen Access
Mapping the Drug Combination Landscape for AML: An Integrative Ex Vivo Functional and Computational Approach
Blood·2024· 1 citedOpen Access
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia
Nature Communications·2024· 18 citedOpen Access
Table S1 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Figure S12 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Figure S8 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Figure S1 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Figure S7 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Figure S6 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Figure S11 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Table S3 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Table S1 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Supplemental Table Legends from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Figure S3 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Data from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Table S3 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
Figure S8 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Kimmo Porkka(35), Olli Kallioniemi(34), Caroline A. Heckman(26), Krister Wennerberg(17), Tero Aittokallio(17), Bhagwan Yadav(15), Mika Kontro(15), Xiao Xian Lin(14), Vedant Sandhu(14), Shruti Bhatt(14), Samuli Eldfors(13), Elyse A. Olesinski(12), Karanpreet Singh Bhatia(12), Chuqi Wang(12), Marissa S. Pioso(12), Shu Xuan Ng(12), Binyam Yilma(12), Stephan Bohl(12), Jeremy Ryan(12), Marlise R. Luskin(12)